Stockscreener 앱 받기
4.81
6.42%
-0.33
시간 외 거래:
4.90
0.09
+1.87%
전일 마감가:
$5.14
열려 있는:
$5.18
하루 거래량:
195.17K
Relative Volume:
2.03
시가총액:
$410.12M
수익:
-
순이익/손실:
$-29.64M
주가수익비율:
-11.19
EPS:
-0.43
순현금흐름:
$-39.43M
1주 성능:
-4.94%
1개월 성능:
+26.25%
6개월 성능:
+62.50%
1년 성능:
+54.17%
1일 변동 폭
$4.7201
$5.2063
1주일 범위
$4.50
$5.2063
52주 변동 폭
$2.30
$5.2063
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
DRTS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
4.81 | 438.26M | 0 | -29.64M | -39.43M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-04-24 | 개시 | H.C. Wainwright | Buy |
| 2022-04-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-04-08 | 개시 | Piper Sandler | Overweight |
| 2022-04-04 | 개시 | Citigroup | Buy |
Alpha Tau Medical Ltd 주식(DRTS)의 최신 뉴스
Alpha Tau Medical’s Innovative Cancer Treatment Study Update: A Potential Game-Changer - TipRanks
Death Cross: Will Alpha Tau Medical Ltd Equity Warrant stock maintain growth story2025 Top Gainers & Risk Controlled Stock Alerts - moha.gov.vn
Alpha Tau Medical’s Innovative Prostate Cancer Therapy: Study Completion Update - TipRanks
Alpha Tau Medical up sharply as brain cancer trial beginsGlobes - Globes - Israel Business News
Alpha Tau treats first US patient with Alpha DaRT for glioblastoma - MSN
Alpha Tau announces first patient treated in study using Alpha DaRT tech - MSN
COO Gat Files To Sell 60,092 Of Alpha Tau Medical Ltd [DRTS] - TradingView — Track All Markets
Is Alpha Tau Medical (NASDAQ:DRTS) Using Debt Sensibly? - simplywall.st
Optimistic Growth Prospects and Strategic Developments Drive Buy Rating for Alpha Tau Medical Ltd - TipRanks
Alpha Tau Medical (NASDAQ:DRTS) Price Target Lowered to $7.00 at Citigroup - Defense World
What's Next For Alpha Tau: Major Milestones Expected Through Early 2026 - RTTNews
Alpha Tau Medical (NASDAQ:DRTS) Given New $7.00 Price Target at Citigroup - MarketBeat
Taking on analysts’ expectations and winning: Alpha Tau Medical Ltd (DRTS) - setenews.com
H.C. Wainwright reiterates Buy rating on Alpha Tau Medical stock By Investing.com - Investing.com Canada
Alpha Tau Medical Just Treated Its First Brain Tumor Patient – and It Could Mark an Inflection Point for the Company (NASDAQ: DRTS) - markets.businessinsider.com
H.C. Wainwright reiterates Buy rating on Alpha Tau Medical stock - Investing.com
Promising Clinical Developments and Innovative Technology Drive Buy Rating for Alpha Tau Medical Ltd - TipRanks
Alpha Tau price target lowered to $7 from $8 at Citi - TipRanks
Alpha Tau Treats First U.S. Brain Cancer Patient With Alpha DaRT; Shares Surge On Breakthrough - Nasdaq
Why Did Alpha Tau Medical (DRTS) Shares Jump Over 25% In After-Hours Trading? - Benzinga
After-Hours Rally: Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers - Nasdaq
Study: Alpha Tau Successfully Treats First Patient with Recurrent Glioblastoma - Imaging Technology News
Alpha Tau Medical Ltd. Successfully Treats First Patient in Its U.S. Trial for Patients with Recurrent Glioblastoma At the James Cancer Hospital At the Ohio State University - marketscreener.com
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University - markets.businessinsider.com
Alpha Tau Treats First U.S. Patient with Alpha DaRT for Glioblastoma - TipRanks
Alpha Tau (Nasdaq: DRTS) gives first Alpha DaRT brain treatment in OSU GBM study - Stock Titan
Alpha Tau Medical (NASDAQ:DRTSW) Trading 6.9% Higher – Here’s What Happened - Defense World
Alpha Tau announces two Alpha DaRT abstracts at ASCO Symposium - MSN
Will Alpha Tau Medical Ltd. Equity Warrant stock outperform international peersMarket Risk Analysis & Real-Time Volume Trigger Notifications - Newser
Is Alpha Tau Medical Ltd. Equity Warrant stock a smart buy before Fed meeting2025 Technical Overview & Reliable Breakout Forecasts - Newser
Why Alpha Tau Medical Ltd. Equity Warrant stock is popular among millennialsMarket Risk Analysis & Low Risk Investment Opportunities - Newser
Will Alpha Tau Medical Ltd. stock rally after Fed decisionsJuly 2025 Outlook & Stock Portfolio Risk Management - Newser
Alpha Tau Medical to Present Pancreatic Cancer Research at 2026 ASCO Symposium - TipRanks
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium - The Manila Times
Alpha Tau Announces Presentation of Two Alpha DaRT - GlobeNewswire
How Alpha Tau Medical Ltd. stock benefits from global expansionMarket Sentiment Summary & Risk Adjusted Buy/Sell Alerts - Newser
Alpha Tau Medical Ltd. Receives FDA Approval to Initiate A Trial for Patients with Locally Recurrent Prostate Cancer - marketscreener.com
Alpha Tau receives FDA approval to initiate a trial for patients with locally recurrent prostate cancer - marketscreener.com
Alpha Tau Medical Receives FDA Approval for Prostate Cancer Trial - TipRanks
Alpha Tau receives FDA approved IDE application to initiate study of Alpha DaRT - TipRanks
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer - The Manila Times
Alpha Tau (NASDAQ: DRTS) gains FDA IDE to test Alpha DaRT in recurrent prostate cancer - Stock Titan
Alpha Tau to Participate in December Investor Conferences - The Manila Times
COO Gat Files To Sell 16,000 Of Alpha Tau Medical Ltd [DRTS] - TradingView
What insider trading reveals about Alpha Tau Medical Ltd. stockJuly 2025 Momentum & Safe Capital Growth Stock Tips - moha.gov.vn
HC Wainwright Has Negative Outlook for DRTS FY2025 Earnings - MarketBeat
What is HC Wainwright’s Forecast for DRTS FY2025 Earnings? - Defense World
Alpha Tau Medical (NASDAQ:DRTS) Receives Buy Rating from HC Wainwright - Defense World
HC Wainwright Reaffirms Buy Rating for Alpha Tau Medical (NASDAQ:DRTS) - MarketBeat
Promising Developments and Strategic Trials Support Buy Rating for Alpha Tau Medical Ltd. - TipRanks
Alpha Tau Medical Reports Q3 2025 Progress and Financials - MSN
Alpha Tau Medical Ltd (DRTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.18%
0.62%
자본화:
|
볼륨(24시간):